Attached

October 01, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Update on Acquisition of stake in SN Genelab Private Limited Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, With reference to the captioned subject and in continuation to our earlier intimation dated September 24, 2026, wherein we have informed that the Board of Directors of the Company has approved for acquisition of stake in SN Genelab Private Limited (“SN Gene”). We wish to inform you that the Company has completed the said acquisition on October 01, 2026, as per the terms and conditions of the Agreement. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, have already been duly intimated in the earlier intimation dated September 24, 2026. We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer